The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To Nirmatrelvir-Reference-Cited by-同舟云学术

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

Published:2023-02-28 Issue:1 Volume:14 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Jochmans Dirk¹^ORCID,Liu Cheng²,Donckers Kim¹,Stoycheva Antitsa²,Boland Sandro³,Stevens Sarah K.²,De Vita Chloe²,Vanmechelen Bert⁴^ORCID,Maes Piet⁴^ORCID,Trüeb Bettina⁵,Ebert Nadine⁵⁶,Thiel Volker⁵⁶,De Jonghe Steven¹,Vangeel Laura¹,Bardiot Dorothée³,Jekle Andreas²,Blatt Lawrence M.²,Beigelman Leonid²,Symons Julian A.²,Raboisson Pierre⁷,Chaltin Patrick³⁸,Marchand Arnaud³,Neyts Johan¹⁹^ORCID,Deval Jerome²,Vandyck Koen⁷

Affiliation:

1. KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium

2. Aligos Therapeutics, Inc., South San Francisco, California, USA

3. CISTIM Leuven vzw, Leuven, Belgium

4. KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium

5. Institute of Virology and Immunology, University of Bern, Bern, Switzerland

6. Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland

7. Aligos Belgium BV, Leuven, Belgium

8. Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium

9. Global Virus Network (GVN), Baltimore, Maryland, USA

Abstract

Paxlovid is the first oral antiviral approved for treatment of SARS-CoV-2 infection. Antiviral treatments are often associated with the development of drug-resistant viruses.

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.02815-22

Reference39 articles.

1. What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design

2. The substrate specificity of SARS coronavirus 3C-like proteinase

3. The SARS-CoV-2 main protease as drug target

4. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection

5. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system;Antiviral Research;2024-11

2. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA;Antiviral Research;2024-10

3. A comprehensive study of SARS-CoV-2 mfigain protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system;PLOS Pathogens;2024-09-11

4. A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity;Scientific Reports;2024-09-05

5. Pomotrelvir and Nirmatrelvir Binding and Reactivity with SARS‐CoV‐2 Main Protease: Implications for Resistance Mechanisms from Computations;Angewandte Chemie;2024-09-03